Centre Hospitalier Emile Muller de Mulhouse
- Address
- 20 Rue du Docteur Laennec - BP 1370, 68070 Mulhouse, France
Centre Hospitalier Emile Muller de Mulhouse - Oncology & Hematology Research
The Centre Hospitalier Emile Muller de Mulhouse is a leading French medical institution with specialized expertise in advanced oncology and hematology clinical research. The center demonstrates particular strength in investigating novel therapeutic approaches for complex malignancies, participating in multi-center phase II and III trials that evaluate innovative treatment combinations and protocols.
- Multiple myeloma treatment strategies for transplant-ineligible elderly patients, focusing on minimal residual disease assessment
- Locally advanced anal squamous cell carcinoma with combined modality approaches including induction chemotherapy and chemoradiotherapy
- Novel drug delivery systems and combination immunotherapy regimens in hematologic malignancies
The center's research portfolio emphasizes precision medicine approaches in hematologic cancers, particularly in multiple myeloma where they investigate cutting-edge combinations of isatuximab, lenalidomide, bortezomib, and dexamethasone. Their work in gastrointestinal oncology includes evaluating intensified treatment strategies for locally advanced anal cancer, contributing to the PRODIGE national research cooperative group. The institution's commitment to serving elderly and non-transplant-eligible patient populations reflects a dedication to improving outcomes across diverse patient demographics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Unicancer1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Emile Muller de Mulhouse
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Pembrolizumab Versus Observation in Early Triple-Negative Breast Cancer with Pathologic Complete Response Post-Neoadjuvant Therapy | Unicancer | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 2 | Unknown | 2021-06-11 | 2024-11-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.